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Abstract 
 
Introduction: Neuropsychiatric symptoms are one of the most common non-motor symptoms in 
3DUNLQVRQ¶V'isease (PD). These symptoms have a negative impact on daily living activities and 
cognitive abilities. This review will be centred on published articles which focused on clarifying the 
cognitive and neuroanatomical features associated with the appearance of specific neuropsychiatric 
symptoms in this disease.   
 
Methods: All articles indexed in the Web of Science and PubMed databases were reviewed for 
potential inclusion in October 2014. In the first stage of the review, we identified 41 articles that 
investigated neuropsychiatric symptoms and cognitive impairments in PD. In the second stage, there 
were 26 published articles on the neural bases of neuropsychiatric symptoms in PD. 
 
Results: The main findings revealed that executive dysfunctions were common in patients with 
depression, apathy, Visual Hallucinations (VH), Impulse Control Disorders (ICDs) and anxiety. 
Whereas, memory deficits were associated mainly with depression and VH. Imaging studies have 
shown that frontal lobe atrophy was frequently observed in patients with depression, apathy, VH and 
ICDs.      
 
Conclusion: This review gives a snapshot of those cognitive and neural correlates of neuropsychiatric 
symptoms in PD. Methodological shortcoming in the available studies were identified, however, of 
which the most critical appeared neglecting the presence of multiple neuropsychiatric symptoms in 
some of the patients included in studies of specific individual symptoms. Additionally, in most studies 
only patients in the moderate to severe stages were included which limits possible inferences to the 
early stage of the disease.   
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Highlights 
 
x Neuropsychiatric symptoms are the most common non-motor symptoms LQ 3DUNLQVRQ¶V
Disease (PD) 
 
x The most common neuropsychiatric symptoms in PD are depression, hallucination, anxiety 
and apathy  
 
x Neuropsychiatric symptoms in PD are associated with deficits in executive functions and 
working memory 
 
x Frontal atrophy or dysfunction are the most frequently detected neural correlates of 
neuropsychiatric symptoms in PD 
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Introduction 
Neuropsychiatric symptoms are common in patients with 3DUNLQVRQ¶VGLVHDVH (PD). A recent 
published study reported that 89% of PD patients with dementia presented with at least one 
neuropsychiatric symptom [1]. These symptoms cause impairments in daily living activities equal to 
or more than the limitations that result from motor deficits, and may lead patients to earlier admission 
to residential care [2-4]. Neuropsychiatric symptoms also occur even in the early stages of the disease. 
Prior research has suggested that these symptoms frequently go unrecognised by clinicians and remain 
untreated [5].  
It has been reported that neuropsychiatric symptoms have a negative impact on cognitive 
abilities in PD patients. However, the link between the presence of specific neuropsychiatric 
symptoms and specific cognitive impairments needs to be reviewed as well as gaining a thorough 
understanding of the neural bases of specific symptoms, since prior studies used different 
methodologies and consequently produced inconsistent findings. Existing review articles on this topic 
focused mainly on a few neuropsychiatric symptoms and reviewed only either the neuropsychological 
or the neural correlates of those symptoms in PD, but did not cover the range of possible symptoms 
that can be observed in this disease and did not look for a parallel between brain atrophy or 
dysfunction and cognitive deficits within the same sample of patients [6-12].  
The present review will cover the most common psychiatric manifestations observable in PD, 
and will also attempt a comprehensive overview of their cognitive and neural aspects. More 
specifically, the review will cover depression, apathy, psychosis, Impulse Control Disorders (ICDs) 
and anxiety [13]. In detail the review addresses some important issues including how specific 
neuropsychiatric symptoms may affect cognitive abilities in patients with PD; and what specific 
regional brain atrophy or dysfunction may underlie a specific symptom in PD. The review will 
highlight any limitations in the literature which might be helpful to suggest directions for future work.   
Method 
Articles were identified by carrying out a comprehensive review of published research papers 
that have investigated the cognitive and neural correlates of neuropsychiatric symptoms in PD. The 
present online literature search of the Web of Science and PubMed databases was carried out in 
October 2014. This search was completed in two stages; the time span for the first stage of search was 
from 1986 to 2014, whereas for the second stage was from 1994 to 2014. Firstly, a search for 
published papers about neuropsychiatric symptoms and cognitive impairments in PD was carried out 
using the following keywords: 3DUNLQVRQ¶VGLVHDVHQHXURSV\FKLDWULFV\PSWRPVGHSUHVVLRQDSDWK\
psychosis, hallucinations, impulse control disorders, anxiety, cognitive impairments and cognitive 
decline. The initial search identified 1275 titles and abstracts. Then we excluded 217 duplicate 
publications. The abstracts and full reports were reviewed to eliminate articles according to the 
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following exclusion criteria: (1) studies that did not focus on cognitive abilities, for instance some 
studies were focused on other aspects such as prevalence, clinical correlates and managements, (2) 
review articles, (3) papers that did not include patients with a diagnosis of PD, (4) the investigation of 
other non-motor symptoms or other neuropsychiatric symptoms that were not specified in this review, 
(5) non-peer reviewed articles and (6) articles which were not written in the English language. In 
total, 41 articles met our inclusion criteria (See figure 1 and tables 1, 2 and 3).  
 
- Insert Figure 1 and Tables 1, 2 and 3 about here - 
 
The second stage was to look for published articles on the neural bases of neuropsychiatric 
symptoms in PD using the same key words except for the words cognitive impairments and cognitive 
decline but including Magnetic Resonance Imaging (MRI), Voxel-Based Morphometry (VBM), 
Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) 
instead. We identified 338 titles and abstracts, and then we excluded 43 duplicate articles. Almost the 
same exclusion criteria for the first stage were used for the second stage of the review. Specifically, 
criteria 2 to 6 were used, but also articles that did not use any neuroimaging techniques had to be 
excluded. After applying these exclusion criteria there were 26 studies that met criteria (See figure 2 
and table 4). 
 
- Insert Figure 2 and Table 4 about here - 
 
 
Results 
According to Aarsland et al. [14] the overall prevalence of neuropsychiatric symptoms in PD 
patients is 61%. The most common symptoms are depression (38%), hallucinations (27%), anxiety 
(20%) and apathy (16.5%). The less common symptoms are euphoria (7.0%) and disinhibition (6.5%). 
A more recent study [15] found that the prevalence of neuropsychiatric symptoms in early untreated 
PD patients was 56%. The most common symptoms reported in this study were depression (37%), 
apathy (27%), sleep disturbance (18%) and anxiety (17%), whereas, psychotic symptoms were found 
to be very rare among untreated PD patients [15]. In PD patients with dementia the prevalence of 
neuropsychiatric symptoms was found to be higher. In the Aarsland et al study, 50 out of 139 patients 
were demented [14] and in a further study, Leroi et al [16] reported that 96% of PD patients with 
dementia presented with at least one neuropsychiatric symptom. Another study demonstrated an 
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association between the total Neuropsychiatric Inventory (NPI) score [17] and depression and anxiety 
(as measured by the Hospital Anxiety and Depression Scale) [18] in non-demented PD patients. Also, 
the presence of neuropsychiatric symptoms was independently predicted by a longer disease duration 
and more severe stage of PD [19].  
1. COGNITIVE CORRELATES OF NEUROPSYCHIATRIC SYMPTOMS IN PD 
1.1 DEPRESSION 
Depression is the most common neuropsychiatric symptom in PD patients [15]. It has been 
indicated that the prevalence rate of depression in this disease is approximately 40% [14, 20, 21]. 
Several studies have demonstrated an association between depression and cognitive impairments in 
PD patients [22-30]. There are, however, a few other studies that did not detect a significant 
association between depression and variance in cognitive deficit in PD (See table 1) [31-34]. In this 
disease, cognitive deficits may occur as a form of global cognitive decline or as an impairment of 
specific cognitive domains. For example, some researchers have found that higher depression scores 
negatively correlated with lower scores on the Mini Mental State Examination (MMSE) [23, 24], 
(Patients included in the first study  [23] had mild to severe disease stages with an average disease 
duration of 7 years, whereas in the second study [24] patients had mild to moderate disease stages 
with an average disease duration of 8.45 years), the Dementia Rating Scale [23, 24, 28] (In the third 
of these studies [28] patients had mild to severe disease stages with an average disease duration of 
11.3 years, patients also were taking Levodopa medication), and the Wechsler Adult Intelligence 
Scale [29] (In this study patients had mild to moderate disease stages). However, these findings are 
not in line with other studies that found no relationship between depression and overall cognitive 
skills in PD [22, 27] (In both these latter studies patients had mild to moderate disease stages).  
Deficits of specific cognitive domains in depressed PD patients mainly involved the 
impairment of executive functions, attention and memory. In terms of executive dysfunction, several 
studies have reported that patients with depression performed significantly lower than non-depressed 
patients on tests of executive function including the Wisconsin Card Sort Test (WCST) [35], 
Controlled Word Association Test-FAS [36], Trail Making Test (TMT) (A and B) [37], Verbal 
Fluency, Abstract Reasoning, Design Fluency Test (Free condition) [38] and the Symbol Digit 
Modalities [39], [25, 28, 30] . Other studies have also demonstrated that depressed PD patients had 
lower scores relative to non-depressed PD patients using a variety of executive tasks e.g. Letter 
Fluency, Abstract Reasoning and Card Sorting Test [22], Category Fluency Test and TMT [29], set-
shifting and response inhibition [40], Frontal Assessment Battery and Stroop test [27]. As for deficits 
in other cognitive domains, earlier studies have reported an association between depression and 
poorer scores on tasks of attention (assessed by a subtest of the Dementia Rating Scale and Digit Span 
Forward) [25, 26], short-term memory (measured by Digit Span Forward and Backward) [30], and 
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memory which was assessed by the Word-list recall and recognition test [22], Hopkins Verbal 
Learning Test  [24, 41], a subtest of the Dementia Rating Scale [26] and the Pattern Recognition 
Memory Task [29]. In addition, another study indicated a relationship between depression and poorer 
performance on a range of cognitive tasks including those testing executive function (Trail Making 
Test), memory (Rey Auditory Verbal Learning Test) and visuospatial skills (Rey-Osterreith Complex 
Figure Test) [42]. 
Despite the amount of research which has examined the association between depression and 
cognitive functions in PD, various shortcomings in these studies limit the validity of their conclusions. 
These limiting factors include failing to exclude patients who presented with multiple 
neuropsychiatric symptoms, a small number of participants in some studies and the use of screening 
instruments that measure limited cognitive functions. Furthermore, prior work did not focus on the 
early stages of the disease, most of the studies recruited patients with heterogeneous levels of severity 
ranging from mild to severe stages.   
1.2 APATHY 
In the literature, it has been demonstrated that apathy is associated with cognitive dysfunction 
[15, 41, 43-53] (See table 2), depression [44-46, 50, 51, 53-56] and anxiety [57]. Although apathy and 
depression can co-exist in PD, several studies have found that apathy may occur in isolation in the 
absence of depression [15, 45, 46, 51, 53, 56, 58-60].  
Apathy in PD patients has been found to be associated mainly with executive dysfunction [15, 
41, 44, 45, 49, 52, 53, 57]. For instance, Aarsland et al. [14] examined cognitive functions in PD 
patients with and without dementia. Apathy was found to be significantly associated with dementia 
and an executive function task, i.e. the Stroop test [14]. Other studies found that apathy was 
significantly associated with executive dysfunctions, evaluated with the Executive Interview [61] and 
category and letter fluency [45] (In this study patients were treated with Levodopa and their average 
disease duration was 4.3 years). Dujardin and colleagues [44] evaluated cognitive functions in non-
demented PD patients (Average disease duration was 9.4 years and they were treated with Levodopa). 
They concluded that after an 18 month follow-up, apathetic PD patients had more cognitive deficits, 
mainly executive dysfunction (measured by the Stroop test) and were more likely to meet the criteria 
for dementia compared with non-apathetic PD patients [44]. Memory deficits have also been observed 
in apathetic PD patients without dementia. These were detected with tasks of immediate free recall, 
short and long delay free recall, long delayed cued recall, delayed recognition (evaluated by the 
California Verbal Learning Test) [62], and digit span backward [52] (In this study patients had mild to 
severe disease stages, their average disease duration was 5.9 years and they were treated with 
Levodopa). A recently published study showed that patients with akinetic-rigid type PD who 
manifested apathy performed significantly worse on tasks of frontal lobe function e.g. the FAB [63], 
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letter fluency [64] and interference error on the Stroop test [65] compared with patients with tremor-
dominant type PD [47].  
A further study reported that in patients with PD with left-side onset (Patients had mild to 
moderate disease stages, their average disease duration was 8.4 years and they were treated with 
Levodopa), apathy scores significantly correlated with scores on non-verbal tasks of e.g. executive 
function, assessed by the TMT (part B) and attention, measured by the Visual Symbol Search Test 
[57]. Robert and others [66] reported that apathy scores were negatively correlated with emotional 
facial recognition scores in patients with PD. However, Robert et al [67] found that apathy did not 
correlate with executive functions (assessed by the Wisconsin Card Sorting Test, TMT, category and 
letter fluency tests and the Stroop test) in non-demented PD patients. Other studies have reported an 
association between apathy and global cognitive impairment (measured by the MMSE and the 
Cambridge Examination for Mental Disorders of the Elderly part B) in PD patients [46, 50]. More 
recently published papers have found that apathetic PD patients had lower scores on tasks of frontal 
functions (evaluated by the Frontal Systems Behaviour Scale and the Stroop test) [68, 69] and 
visuospatial functions (assessed by the Constructional Apraxia Task and the Benton Judgment of 
Lines Orientation Task) [69] when compared to non-apathetic PD patients. 
In the literature, studies of apathy and cognitive abilities in PD patients did not take PD 
severity into account. In other words, previous studies have not explored the association between 
apathy and cognitive skills in the early stages of PD, but they have taken a broad definition of the 
disease and included patients at different severity levels. Further, earlier studies have used a limited 
number of participants or used general cognitive measurements which do not assess a broader range 
of cognitive domains. In patients with PD, the development of NPS has been frequently linked to the 
use of antiparkinsonian treatments but not to dementia [70, 71]. There are several pieces of evidence 
which support the hypothesis that cognitive impairments and dementia are a consequence of the 
development of NPS in general and apathy in particular [14, 41, 43-45, 47-53, 72]. For instance, a 
recent study [16] explored the frequency of NPS in three groups of patients with PD; patients without 
cognitive impairment (PD-NC, n = 54), patients with mild cognitive impairment (PD-MCI, n = 48) 
and patients with dementia (PDD, n = 25). Patients who showed at least one NPS were 39 (72.2%) in 
the PD-NC group, 38 (79.2%) in the PD-MCI group and 24 (96%) in the PDD group. Apathy was 
more frequent in the PD-MCI and PDD groups than the PD-NC group. In this study, apathy was also 
significantly correlated with factors such as advanced stage of disease and dopamine agonist load and 
all cognitive measures used in that study (e.g. Trail Making Test, Verbal Fluency Task, Wisconsin 
Card Sorting Test, 5-minute recall of 3 words and MMSE) [16].  
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1.3 PSYCHOSIS 
The most common psychotic symptom in PD is Visual Hallucination (VH) [73]. Several 
studies have observed cognitive decline in patients with PD who have VH [73-78] (See table 3). For 
example, a study examined the presence of cognitive impairment in non-demented PD patients with 
VH (Mild to moderate disease stages, average disease duration was 6.79 years, average years of PD 
onset was 60.21 and all patients treated with Lovadopa). Patients with VH had significantly lower 
scores relative to patients without VH  in global cognitive abilities assessed by the short test of mental 
status [79], frontal functions, evaluated by the Stroop test [65], category fluency task [64], the clock 
drawing test [80] and nonverbal memory assessed by the Visual reproduction subtest of the Wechsler 
memory scale [81]. However, there were no significant differences between the two PD subgroups in 
visual perceptive functions measured by the Benton face recognition test [82], the Judgement of Line 
Orientation test [83] and one of the frontal functions test which was the Wisconsin Card Sorting Test 
[84]. These results suggest that PD patients with VH might have deterioration in frontal and memory 
functions [76]. Moreover, a further study reported that PD patients with VH had cognitive impairment 
in visual memory tasks (evaluated by the Warrington Recognition Memory for Faces), 
visuoperceptive and visuospatial functions (assessed by the Benton Facial Recognition Test and the 
standard drawing and multiple-choice versions of the Benton Visual Form Discrimination Test 
respectively) compared with PD patients without VH [77] (In this study patients had mild to moderate 
disease stages and treated with Levodopa). A recently published study examined cognitive decline in 
non-demented PD patients with and without VH (Patients were treated with Levodopa, Dopamine 
agonist and Anticholinergic medications). Results revealed that patients with VH performed 
significantly lower than patients without this symptom on tasks of executive function (measured by 
the Stroop test) and delayed recall which was evaluated by the Rey Complex Figure Test [78]. 
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1.4 IMPULSE CONTROL DISORDERS  
Few studies have examined cognitive functioning in PD patients with ICDs. The cognitive 
domain that appears to be mostly impaired in PD patients with ICDs is executive functioning [85-89] 
(See table 3). Biundo and others [85] reported executive dysfunction in PD patients with ICDs 
(Average disease duration was 8.81 years, age at onset was 53.18 and all patients treated with 
dopamine agonist). This cognitive impairment specifically was found in general frontal lobe function 
(detected by the TMT part B) and in shifting abilities as measured by the TMT part B minus part A 
score [85]. Furthermore, other studies have reported memory impairment in PD patients with ICDs, 
particularly, in spatial working memory tasks assessed by the Cambridge Automated 
Neuropsychological Test Battery [89] (In this study the average age at PD onset was 53.49 and 
patients were treated with Levodopa and a dopamine agonist), short-term memory and working 
memory as measured by digit span forward and backward [86]. 
1.5 ANXIETY   
Only two studies have investigated the relationship between anxiety and cognitive functions 
in PD patients [57, 90] (See table 3). The first study reported that left-lateralized PD patients with 
anxiety performed significantly worse than right-lateralized PD patients with anxiety on working 
memory tasks, i.e. the digit span backward subtest of the Wechsler memory scale [90]. The second 
study reported that in PD patients with right-side onset, anxiety scores were significantly correlated 
with verbal deficits including verbal fluency (assessed by the Controlled Word association Test-FAS), 
language and memory (evaluated by the Boston Naming Test and California Verbal Learning Test 
respectively) [57].     
2. NEUROANATOMICAL CORRELATES OF NEUROPSYCHIATRIC SYMPTOMS IN PD 
2.1 DEPRESSION  
We found 11 imaging studies that have explored the neural bases of PD patients with and 
without depression using different imaging techniques [91-101] (See table 4). Among these studies, 
there is only one study that found no differences in brain regions between PD patients with and 
without depression [97] (In this study patients had mild to severe disease stages, average disease 
duration was 4.9 years and age at onset was 62.6). However, other articles reported brain changes in 
depressed PD patients. For instance, a recently published PET study reported that in patients with PD, 
depression scores (as assessed by the Beck Depression Inventory) correlated with increased brain 
metabolism in the amygdala [93]. Other studies have emphasised the important role of the 
dorsomedial prefrontal cortex in a similar group of patients [99]. A PET study found that PD patients 
with depression had decreased cerebral blood flow in the frontal cortex and in the anterior cingulate 
cortex when compared with PD patients without depression and controls [99]. Two VBM studies 
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reported that depressed PD patients had lower grey matter density in the frontal, temporal cortex [92] 
(In this study patients had moderate disease stage, their average disease duration was 9.9 years and 
they were treated with Levodopa), in the posterior cingulate cortex and the hippocampus [94] (This 
study included patients with mild to moderate disease stages, average disease duration was 6 years 
and they were treated with Levodopa). Sheng et al. [100] found that functional connectivity was 
decreased within the prefrontal-limbic system and increased in the prefrontal cortex and lingual gyrus 
in PD patients with depression.   
A limited number of studies have investigated white matter volume in PD patients with 
depression. These studies revealed that PD patients with depression had white matter reductions in the 
right anterior cingulate bundle, inferior orbitofrontal regions and in the left inferior parietal lobe [94], 
the frontal lobe bilaterally, possibly representing dysfunction in bilateral anterior cingulate bundles 
[96], and the mediodorsal nucleus of the thalamus bilaterally [95]. 
In summary, two VBM studies have explored the neural correlates of depression in PD 
patients [92, 94], but these studies have various limitations. For instance, in the Feldmann et al. study, 
PD patients were in the moderate stage of the disease (Hoehn- Yahr, 1967). The exploration of 
depression in patients with early stage of PD may allow for more effective diagnosis and intervention. 
In addition, the earlier studies did not covariate for total intracranial volume, which might have 
contributed to the results of grey matter reduction. Furthermore, the authors relied on reports of 
previous episodes of other neuropsychiatric symptoms in order to exclude patients who had these 
symptoms. Finally, the Kostic et al. study included PD patients in the mild to moderate stages, a very 
small sample size and included 8 patients who were treated with antidepressants [94]. It has been 
reported that antidepressant medications activate specific brain regions which may influence the 
results of neuroimaging studies that investigate depressive symptoms [102]. For instance, a meta-
analysis [103] of fMRI and PET studies has shown that antidepressants in major depression increase 
the activation of dorsolateral, dorsomedial and ventrolateral prefrontal cortices, whereas the activation 
was decreased in the amygdala, hippocampus, parahippocampal, areas, ventral anterior cingulate 
cortex and orbitofrontal cortex. Therefore, it seems that the exclusion of patients who take 
antidepressants is highly recommended in functional neuroimaging studies in order to have more 
precise results.  
2.2 APATHY 
Despite the fact that apathy is probably the most frequently observed neuropsychiatric 
symptom in PD patients, the neural bases of apathy in PD patients remain unclear. We found 7 studies 
that have investigated the underlying mechanism of apathy in PD using a variety of imaging 
techniques [45, 50, 66, 67, 93, 101, 104] (See table 4). A PET study investigated apathy in non-
demented PD patients (Average disease duration at surgery was 11.2 years) after deep brain 
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stimulation of the subthalamic nucleus using the Apathy Evaluation Scale [105]. In this study, 
positive correlations were identified between apathy scores and glucose metabolism in the frontal 
lobe; whereas, apathy scores were negatively correlated with glucose metabolism in the posterior 
cingulate gyrus and the frontal lobe [104]. A VBM study has shown evidence that in PD low grey 
matter density in many cortical brain region within the frontal, parietal, cingulate cortex correlated 
with high apathy scores [50]. An fMRI study investigated the specific characteristics of apathy, 
depression, and motor progression in the resting state of PD patients using the Amplitude of the Low 
Frequency Fluctuation (ALFF). Higher apathy scores were associated with increased normalized 
ALFF signal in the frontal and in the cingulate cortex bilaterally. Conversely, higher apathy scores 
were correlated with decreased activity in the supplementary motor region, the parietal lobule and the 
fusiform gyrus. Severity of depression was correlated with increased normalized ALFF signal in the 
cingulate, the cuneus, the lateral geniculate and the mesial frontal gyrus [101]. 
The involvement of the frontal and cingulate cortex has been constantly observed in PD 
patients with apathy. More recent PET studies have supported this view, for instance, Report el al. 
(2012) found that apathy scores correlated positively with cerebral metabolism in the inferior/middle 
frontal gyrus, cuneus and the insula. Negative correlations were identified between apathy scores and 
cerebral metabolism in the bilateral cerebellum, particularly the inferior semilunar lobule [67]. A 
more recent PET study in PD patients showed that apathy scores correlated with increased 
metabolism in the anterior cingulate and orbitofrontal lobe bilaterally [93]. Robert et al. [66] also 
reported increased metabolism within the posterior cingulate cortex in apathetic patients with PD. 
However, a different study did not identify any specific measure of frontotemporal atrophy correlating 
with the presence or severity of apathy [45].   
To our knowledge, none of the earlier studies has investigated white matter changes in 
SDWLHQWVZLWK3'ZKRKDYHDSDWK\+RZHYHULQRWKHUQHXURORJLFDOGLVRUGHUVVXFKDV$O]KHLPHU¶V
disease this point has been studied with one study reporting that apathetic AD patients had a 
significantly greater amount of frontal white matter hyperintensities than non-apathetic AD patients 
[106]. 
It can be noticed from the above review that the association between apathy and white matter 
volume in PD has not yet been explored. In addition, only one VBM study has investigated grey 
matter volume in PD with apathy but this study had various limitations such as the inclusion of 
patients with only mild apathy scores and the use of only a correlational analysis design. Indeed, there 
is evidence that apathy is associated with atrophy of the frontal and cingulate cortex in PD [50, 104]. 
2.3 PSYCHOSIS 
Most of the earlier imaging studies that attempted to explore psychosis in patients with PD 
focused on the study of visual hallucination [78, 107-113] (See table 4). Previous reports suggest that 
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VH in PD patients can be correlated either with cortical or subcortical atrophy [113]. Specifically, VH 
was associated with dysfunction of frontal lobe [78, 109, 111-113], temporal lobe [78, 110], cingulate 
cortex [112, 113], hippocampus [112], parahippocampal, primary and secondary visual cortex [113], 
thalamus [78], precuneus and cerebellum [111]. A VBM study investigated grey and white matter 
alterations in PD patients with VH (Patients had mild to moderate disease stages, average disease 
duration was 10 years, average age at PD onset 53.6 and they were treated with Levodopa) [113]. This 
study reported grey matter reduction in the prefrontal cortex, cingulate cortex and visual association 
areas in PD patients with VH. The same group of patients showed white matter reduction in the 
parahippocampal gyrus, posterior cingulate gyrus, lingual gyrus and middle occipital gyrus when 
compared with PD patients without VH. However, this study included small number of patients. A 
further study has reported grey matter reduction in the left frontal areas in patients with PD who have 
developed VH when compared with those patients without VH [107] (In this study the average 
disease duration for patients was 5.3 years and average age at PD onset was 63.1). 
2.4 IMPULSE CONTROL DISORDERS 
We found only two imaging studies that have investigated ICDs in PD patients [85, 114] (See 
table 4). The first study reported decreases in the binding potential of a dopaminergic tracer in the 
ventral striatum in PD patients with pathological gambling [114] (This study included patients with 
mild to moderate disease stages and their average disease duration was 7.4 years). Additionally, a 
VBM study examined brain volume changes in PD patients with and without ICDs and healthy 
controls. The Minnesota Impulsive Disorders Interview was used to assess ICDs. When compared 
with controls, PD patients (with and without ICDs), had a significantly lower grey matter volume in 
frontal lobe [85]. 
2.5 ANXIETY  
 Only one recent imaging study has examined the association between anxiety and brain 
metabolism changes in patients with PD (See table 4). Huang et al. (2013) studied the correlation 
between anxiety scores (as assessed by the Beck Anxiety Inventory) [115] and brain metabolism in 
non-demented patients with PD. This study used a Region of Interest (ROI) technique to explore PD-
related regions e.g. the motor cortex, cingulate cortex, occipital lobe, frontal cortex, cerebellum, 
limbic system and temporoparietal association cortex. The anxiety scores correlated with decreased 
metabolism in the caudate nucleus bilaterally [93].    
Discussion  
Most of the prior studies reported differences in cognitive abilities between patients with and 
without neuropsychiatric symptoms; these findings suggest that the presence of neuropsychiatric 
symptoms can affect cognitive skills in this patient population. Particularly, significant differences 
were detected on tests that mainly assess executive functioning (e.g. inhibitory control and working 
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memory), which fit the cognitive profile of patients with frontal lobe dysfunction. Moreover, the 
association between neuropsychiatric symptoms and executive dysfunction has been reported in non-
demented PD patients, [19, 116], again, adding to the conclusion that neuropsychiatric symptoms in 
PD may be associated with specific regional frontal lobe dysfunction and might not necessarily be a 
consequence of overall cognitive impairment.  
In general, there are three core types of executive functions which seem to be repeatedly 
involved and these are inhibitory control, working memory and cognitive flexibility [117]. Thus 
perhaps, the inability to perform well on the tasks that assess executive functions in PD routes from 
poor working memory and a lack of control over the stimuli presented to them in the context of 
prefrontal cortex damage. Furthermore, the atrophy observed within the frontal circuits contributes to 
the manifestation of neuropsychiatric symptoms in PD, leading to poor self-control and a weak 
attention span (including both behavioural and cognitive abnormalities).   
In line with the above, there have been similar patterns of association observed in 
neurodegeneration related to AD type pathology in experiments in which patients with MCI with 
neuropsychiatric symptoms have also been studied with a comprehensive battery of 
neuropsychological tests. For instance, Rosenberg and colleagues  [118] found that the presence of 
executive dysfunction in MCI was associated with greater severity of neuropsychiatric symptoms as 
assessed by the NPI, specifically depression, anxiety, agitation, apathy, disinhibition, irritability, and 
sleep disturbance. This finding is also supported by another study by Ellison et al  [119] who reported 
that the most frequent symptoms were depression/dysphoria, apathy, anxiety, irritability/lability and 
nighttime abnormal behaviour in MCI. Another study [120] showed that MCI patients with a high 
number of neuropsychiatric symptoms (four or more) are more likely than patients with fewer 
symptoms (up to three) to have the amnestic form of MCI, which most likely reflects the presence of 
neurodegeneration leading to AD dementia. Amnestic MCI patients with more neuropsychiatric 
symptoms had a greater risk of developing dementia than those with fewer symptoms.  
A systematic review study of MCI patients indicated that the prevalence of neuropsychiatric 
symptoms ranged from 35% to 75% with the most common being depression, apathy, anxiety and 
irritability [120-122]. These studies also reported that MCI patients with behavioural disturbances are 
more likely to develop AD than patients without these features. Furthermore, Trivedi et al. [123] 
reported that neuropsychiatric symptoms (as measured by the NPI) were significantly more severe and 
frequent in patients with MCI than in healthy participants, and demented patients had significantly 
more neuropsychiatric problems than MCI and healthy groups. Other studies have shown that there 
was a negative association between frequency of neuropsychiatric symptoms and MMSE scores in 
patients with MCI [120, 122]. 
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In view of the findings of the current review and the MCI studies, it can be said that the 
development of neuropsychiatric symptoms goes in parallel with cognitive decline and should be 
thoroughly assessed in patients with cognitive impairment (independently of the underlying 
neurodegenerative aetiology, i.e. whether due to PD or AD). These findings also raise the question of 
whether treatment of neuropsychiatric symptoms in PD or MCI (due to AD) might prevent or delay 
progression to dementia. Further investigations are required to address this point. 
Despite the cognitive investigations were done independently from the imaging studies, a 
speculative attempt can be made to integrate some of the findings from both types of study. For 
instance, Starkstein et al [28] found that depressed PD patients had executive dysfunction which was 
detected by the TMT. This result may reflect less brain activation in the middle frontal gyrus, a 
finding that was reported in the Sheng et al [100] study. This speculation is also supported by an fMRI 
study that found brain activation in the middle frontal gyrus in healthy participants while performing 
the TMT [124]. In addition, the low scores on the letter fluency test found in depressed PD patients in 
the cognitive studies [31, 33] could be explained by brain atrophy in the anterior cingulate gyrus [79, 
80]. The letter fluency task requires the participant to initiate extensive searches for suitable words. 
Also for this task, evidence from fMRI studies is helpful as an association between the anterior 
cingulate cortex and letter fluency performance has been repeatedly reported in healthy participants 
[125-127].       
This review of the literature illustrates studies that have investigated the association between 
cognitive abilities and neuropsychiatric symptoms in patients with PD. However, these studies did not 
control for the presence of other neuropsychiatric symptoms when they investigated a specific 
symptom in patients with this disease. Prior research has provided evidence that neuropsychiatric 
V\PSWRPVLQ3DUNLQVRQ¶VGLVHDVHFDQPDQLIHVWHLWKHUDVLQGHSHQGHQWLVRODWHGV\PSWRPVRUDVPXOWLSOH
co-occurring symptoms. In addition, there are some methodological issues that have been raised 
following studies that examined specific neuropsychiatric symptoms. For instance, when examining 
cognitive decline within a group of patients with a particular neuropsychiatric symptom, it is very 
important to exclude patients who experience multiple symptoms. This approach will allow a better 
understanding of the possible cognitive correlates when breaking down the results for each specific 
symptom. However, most previous work did not take this issue into account. Another point is that 
certain studies assess only global cognitive abilities or limited cognitive domains. Additionally, prior 
investigations did not focus on the early stages of PD when examining these variables. Similar 
methodological issues have been found in some published studies that have explored the brain regions 
that may correlate with specific neuropsychiatric symptoms. 
Future studies should take all the limitations highlighted above into account and especially 
study neuropsychiatric symptoms in patients at a much earlier stage of the disease.  It would also be 
an advance if the presence of symptoms were ascertained by using an instrument which can detect 
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also the presence of other concomitant neuropsychiatric symptoms. An instrument such as the 
Neuropsychiatric Inventory [128] for example (or others with similar structure) would allow the 
exclusion of other co-occurring symptoms when exploring a particular feature. In addition, in most of 
the available studies a limited range of cognitive abilities was assessed. The use of an extensive 
neuropsychological battery to explore multiple cognitive domains could provide a clearer picture of 
the cognitive skills which might have deteriorated in non-demented PD patients who develop a 
specific neuropsychiatric symptom or a given set of symptoms. Furthermore, cognitive and 
neuroimaging studies of anxiety in patients with PD are limited. Only two studies have examined the 
cognitive correlates of anxiety in PD [57, 90] but neither of them compared patients with anxiety 
versus patients without any neuropsychiatric symptoms or healthy controls. The underlying 
neurobiological mechanisms of anxiety in PD, therefore, have yet to be explored, which is something 
that could add a further dimension to the investigation and clarification of the causes of 
neuropsychiatric symptoms in PD.  
The overall underlying mechanisms of neuropsychiatric symptoms in PD are still unclear. 
Although there are several published studies which have investigated the neural correlates of 
neuropsychiatric symptoms using different approaches, little is known about the structural brain areas 
that may associate with these symptoms. It has been reported that a VBM approach offers a suitable 
way to explore grey and white matter volume changes as it has been championed for its powerful 
unbiased hypothesis testing approach across the whole brain [129]. Finally, a combination of both 
neuropsychological and more advanced imaging techniques (i.e. diffusion tensor imaging and resting 
state fMRI) in exploring neuropsychiatric symptoms in the same cohort of patients with PD might 
provide a better understanding of both the cognitive and the neural breakdowns associated with the 
genesis of neuropsychiatric symptoms in the early stages of PD. 
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Table 1: Summary of articles included in the review (Cognitive performance in PD with depression)  
Authors NPSS Number of 
participants 
NPSS 
Assessments 
Cognitive domain 
targeted 
Cognitive 
tests 
Impaired 
cognitive 
performance 
Taylor et al. 
(1986) [32] 
Depression 15 PD with 
depression 
15 PD without 
depression  
Beck 
Depression 
Inventory 
(BDI) DSM-
III    
Short-term 
memory 
Digit span No 
differences 
Starkstein 
et al. (1989) 
[28] 
Depression 15 PD with major 
depression 
19 PD with minor 
depression   
44 PD without 
depression 
Hamilton 
Rating Scale 
for 
Depression 
(HRSD)  
DSM-III 
Global cognitive 
ability 
Executive 
function  
Attention 
MMSE 
WCST 
TMT 
Digit span 
All 
cognitive 
domains  
Troster et 
al. (1995) 
[34] 
Depression 45 PD with 
depressed 
45 PD patients 
without 
depression  
BDI Conceptualisation 
Initiation 
Construction  
Memory 
Subtests of 
Dementia 
Rating Scale 
No 
differences   
Troster et 
al. (1995) 
[33] 
Depression 44 PD with 
depressed 
44 PD patients 
without 
depression   
BDI Executive 
function 
Attention 
Memory 
Immediate and 
delayed recall 
WCST 
Digit span 
Logical 
Memory Test 
part of WAIS 
Boston 
Naming Test 
No 
differences   
Kuzis et al. 
(1997) [25] 
Depression 19 PD with 
depression 
31 PD without 
depression 
27 with 
depression only 
HRSD Executive 
function 
Attention  
Abstract 
reasoning  
COWAT-FAS 
Digit span 
RPM 
Verbal 
fluency 
Attention 
Abstract 
reasoning 
Cubo et al. 
(2000) [23] 
Depression 88 PD HRSD Global cognitive 
ability 
MMSE 
 
Global 
cognitive 
ability 
Norman et 
al. (2002) 
[26] 
Depression 35 PD BDI Global cognitive 
ability 
DRS Global 
cognitive 
ability 
Uekermann 
et al. (2003) 
[30] 
Depression 12 PD with 
depression 
16 PD without 
depression 
14 with 
depression only 
BDI Executive 
function 
Memory  
General 
intellectual 
functioning  
Letter Fluency 
Test 
Digit span 
WAIS 
Executive 
dysfunction   
Short-term 
memory  
Concept 
formation 
Costa et al. 
(2006) [22] 
Depression 18 PD with major 
depression 
21 PD with minor 
depression  
32 PD without 
depression 
DSM-IV 
BDI  
Global cognitive 
ability 
Memory 
Executive 
functions 
Abstract 
reasoning 
Visual-spatial  
Language 
MMSE 
Word-list 
recall and 
recognition  
Letter Fluency 
Test 
RPM 
&RSLQJ5H\¶V
figure form 
Sentence 
Construction 
Test 
Global 
cognitive 
ability 
Long-term 
verbal 
episodic 
memory  
 Abstract 
Reasoning 
 
Verbal 
fluency 
Stefanova Depression 16 PD with major DSM-IV  Global cognitive WAIS Global 
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et al. (2006) 
[29] 
depression 
10 PD with minor 
depression 
54 PD without 
depression 
HRDS functioning 
Memory  
Executive abilities 
Language  
Visual 
organisation  
RAVLT 
TMT 
Letter and 
Category 
Fluency Tests 
Boston 
Naming Test 
Spatial 
Working 
Memory Test 
Pattern 
Recognition 
Memory Test 
cognitive 
ability 
Verbal 
fluency 
Cognitive 
flexibility 
Working 
memory 
 Language 
Spatial 
recognition 
Silberman 
et al. (2007) 
[31] 
Depression 18 PD with 
depression 
28 PD without 
depression 
DSM-IV  
HRSD 
Executive 
function 
  
Stroop Test Response 
inhibition 
Set-shifting 
 
Santangelo 
et al. (2009) 
[27] 
Depression 65 PD with 
depression 
60 PD without 
depression  
DSM-IV  
HRSD 
Executive 
function 
Stroop Test 
FAB 
Response 
inhibition 
Set-shifting 
Inhibitory 
control 
Fernandez 
et al. (2009) 
[24] 
Depression 82 PD BDI Global cognitive 
ability 
Attention 
Memory  
Processing speed  
Language  
Executive 
function 
Visual-spatial 
processing 
MMSE 
DRS 
Digit span 
HVLT 
TMT 
Judgment of 
Line 
Orientation 
Test 
Face 
Recognition 
Test 
Global 
cognitive 
ability 
Word-list 
delayed 
recall  
Language 
NPSS: neuropsychiatric symptoms, DSM: Diagnostic and Statistical Manual of Mental Disorders, MMSE: Mini Mental 
State Examination, WCST: Wisconsin Card Sorting Test, TMT: Trail Making Test, WAIS: Wechsler Adult Intelligence 
Scale, COWAT: Controlled Oral Word Association Test, RPM: 5HYDQ¶V 3URJUHVVLYH 0DWULFHV, DRS: Dementia Rating 
Scale, FAB: Frontal Assessment Battery, HVLT: Hopkins Verbal Learning Test.  
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Table 2: Summary of articles included in the review (Cognitive performance in PD with apathy)  
Authors NPSS Number of 
participants 
NPSS 
Assessments 
Cognitive 
domain 
targeted 
Cognitive tests Impaired 
cognitive 
performance 
Starkstein et 
al. (1992) 
[51] 
Apathy 45 PD  AES Executive 
functions 
COWAT-FAS 
 
 Verbal fluency 
Levy et al. 
(1998) [15] 
Apathy 40 PD 
30 AD 
28 Frontotemporal 
dementia 
22 Progressive 
supra-nuclear palsy 
NPI Global 
cognitive 
ability 
MMSE Global 
cognitive ability 
Aarsland et 
al. (1999) 
[15] 
Apathy 139 PD NPI Global 
cognitive 
ability 
Executive 
functions 
MMSE 
Stroop Test 
 
Global 
cognitive ability 
Pluck & 
Brown (2002) 
[49] 
Apathy 45 PD 
 
AES Executive 
functions 
Stroop Test 
COWAT-
Category Test 
Response 
inhibition 
Set-shifting 
Verbal fluency 
Isella et al. 
(2002) [45] 
Apathy 30 PD AES Executive 
functions 
Letter and 
Category 
Fluency Tests 
Verbal fluency 
Zgaljardic et 
al. (2007) 
[53] 
Apathy 32 PD 
 
AES Executive 
functions 
Letter and 
Category 
Fluency Tests 
Digit span 
Verbal fluency 
Attention  
Dujardin et 
al. (2009) 
[44] 
Apathy 20 PD with apathy 
21 PD without 
apathy 
LARS Executive 
functions 
Stroop Test 
Letter and 
Category 
Fluency Tests 
Response 
inhibition 
Processing 
speed 
Verbal fluency 
Reijnders et 
al. (2010) 
[50] 
Apathy 55 PD AES Global 
cognitive 
ability 
MMSE 
CAMCOG 
No correlation  
Butterfield et 
al. (2010) 
[41] 
Apathy 68 PD AES Executive 
functions 
Memory 
WCST 
HVLT-R 
Problem-solving 
Word-list 
delayed recall 
Varanese et 
al. (2011) 
[52] 
Apathy 23 PD with apathy 
25 PD without 
apathy 
AES Executive 
functions  
Memory 
WCST 
Digit span 
CVLT 
Set-shifting 
Working 
memory 
Word-list 
delayed recall 
Moretti et al. 
(2012) [47] 
Apathy 103 PD NPI and AES Executive 
functions 
Letter Fluency 
Test  
Stroop Test 
FAB 
Verbal fluency 
Response 
inhibition 
Set-shifting 
Bogdanova & 
Cronin-
Golomb 
(2012) [57] 
Apathy 22 PD AES Attention 
Executive 
functions 
Visuospatial 
Language 
Memory 
Visual Symbol 
Search Test 
TMT 
Letter Fluency 
Test 
RCPM 
CVLT 
Attention 
Visuospatial 
 
Robert et al. 
(2012) [26] 
Apathy 45 PD AES Executive 
functions 
Stroop Test 
TMT 
WCST 
Letter and 
Category 
Fluency Tests 
No correlation 
Robert et al. 
(2014) [66] 
Apathy 36 PD AES Emotional 
facial 
recognition 
EFR Task Emotional facial 
recognition 
Santangelo et Apathy 62 PD AES Memory 5H\¶V-word Frontal 
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al. (2014) 
[69] 
Frontal 
functions 
Visuospatial 
Test 
Stroop Test 
Constructional 
Apraxia Task 
BJLOT 
functions 
Visuospatial  
 
Buelow et al. 
(2014) [68] 
Apathy 24 PD Frontal 
Systems 
Behaviour 
Scale 
Decision 
making 
Iowa Gambling 
Task 
Decision 
making 
NPSS: neuropsychiatric symptoms, AES: Apathy Evaluation Scale, NPI: Neuropsychiatric Inventory, LARS: Lille Apathy 
Rating Scale, MMSE: Mini Mental State Examination, CAMCOG: Cambridge Cognitive Examination, WCST: Wisconsin 
Card Sorting Test, CVLT: California Verbal Learning Test, TMT: Trail Making Test, COWAT: Controlled Oral Word 
Association Test, RCPM: 5HYDQ¶V Coloured Progressive Matrices, Scale, FAB: Frontal Assessment Battery, HVLT-R: 
Hopkins Verbal Learning Test Revised, EFR: Emotional Facial Recognition, BJLOT: Benton Judgment Line Orientation 
Test. 
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Table 3: Summary of articles included in the review (Cognitive performance in PD with 
Hallucinations, ICDs and anxiety)  
Authors NPSS Number of 
participants 
NPSS 
Assessments 
Cognitive 
domain 
targeted 
Cognitive Tests Impaired 
cognitive 
performance 
Grossi et al. 
(2005) [73] 
Hallucinations 9 PD with VH 
2 PD with 
Auditory 
hallucination 
3 PD with both 
types of 
hallucinations 
34 PD without 
hallucinations 
DSM-IV Executive 
functions 
Learning 
Memory 
Abstract 
Thinking 
Letter and 
Category Fluency 
Tests 
5H\¶V-word 
test 
RCPM 
Verbal fluency 
Word-list 
immediate 
recall 
Ramirez-
Ruiz et al. 
(2007) [77] 
VH 20 PD with VH 
20 PD without 
VH 
DSM-IV Global 
cognitive 
ability 
Memory 
Spatial 
functions 
MMSE 
WRMF 
BFRT 
BVFDT 
Visual memory 
Visuoperceptive
-visuospatial 
45% developed 
dementia after 
one year 
Ozer et al. 
(2007) [76] 
VH 33 PD with VH 
30 PD without 
VH 
Unified 
3DUNLQVRQ¶V
disease 
Rating Scale 
Global 
cognitive 
ability  
Memory 
Frontal 
functions 
 
Short test of 
Mental Status  
Stroop Test 
Category Fluency 
Test  
Clock Drawing 
Test 
WCST 
BJLOT 
BFRT 
Global 
cognitive ability 
Verbal fluency 
Set-shifting 
Response 
inhibition 
Verbal memory 
Bronnick et 
la. (2011) 
[74] 
VH 86 PD with 
dementia 
NPI Executive 
functions 
Working 
Memory 
Visuospatial 
Attention 
D-KEFS 
Serial7s task from 
MMSE 
Visual 
Construction Task 
subtest of ADAS-
Cog 
Go/no-go test 
response 
processes 
Shin et al. 
(2012) [78] 
VH 46 PD with VH 
64 PD without 
VH 
NPI Executive 
functions 
Memory 
Stroop Test 
Rey Complex 
Figure Test 
Set-shifting 
Response 
inhibition 
Delayed recall 
Hepp et al. 
(2013) [75] 
VH 31 PD with VH 
31 PD without 
VH 
Scales for 
Outcome in 
Parkinson 
Disease 
Executive 
functions 
Memory 
TMT 
Rey 15-word test 
Visuo-motor 
speed 
Immediate 
recall 
Santangelo 
et al. (2009) 
[87] 
ICDs 15 PD with 
ICDs 
15 PD without 
ICDs 
DSM-IV Frontal 
functions 
Memory 
Abstract 
thinking 
FAB  
TMT 
Letter and 
Category Fluency 
Tests 
WCST 
Rey Complex 
Figure Test 
RCPM 
Cognitive 
flexibility 
Set-shifting 
Abstract 
thinking 
Delayed recall 
Spatial planning 
Djamshidian 
et al. (2010) 
[86] 
ICDs 18 PD with 
ICDs 
12 PD without 
ICDs 
DSM-IV Memory 
Learning 
Digit span 
Associative 
Learning Task 
Working 
memory 
Vitale et al. 
(2011) [88] 
ICDs 45 PD with 
ICDs 
Minnesota 
Impulsive 
Disorders 
Interview 
Frontal and 
executive 
functions 
Memory 
TMT 
WCST 
Stroop Test 
Rey Complex 
Figure-Copying 
Task 
Rey 15-word test 
Spatial planning   
Set-shifting 
Cognitive 
flexibility 
Inhibitory 
control 
Immediate and 
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delayed recall 
Biundo et 
al. (2011) 
[85] 
ICDs 33 PD with 
ICDs 
24 PD without 
ICDs 
Minnesota 
Impulsive 
Disorders 
Interview 
Global 
cognitive 
abilities  
Memory  
visuospatial 
Abstract 
reasoning  
attention 
MMSE 
TMT 
Rey Complex 
Figure Test 
Similarities Task 
RCPM 
Digit span 
Set-shifting 
General lobe 
function 
 
 
Voon et al. 
(2010) [89] 
ICDs 14 PD with 
ICDs 
14 PD without 
ICDs 
DSM-IV Spatial 
working 
memory 
Set-shifting 
 
CANTB 
Intra-
extradimensional 
set shifting task 
Spatial working 
memory 
 
Foster et al. 
(2010) [90] 
Anxiety 59 PD State-trait 
Anxiety 
Inventory 
Memory Digit span Working 
memory 
Bogdanova 
& Cronin-
Golomb 
(2012) [57] 
Anxiety 22 PD Beck 
Anxiety 
Inventory 
Executive 
functions 
Attention 
Visuospatial 
Language 
Memory 
COWAT-FAS 
TMT 
Digit span 
RCPM 
Boston Naming 
Test 
CVLT 
Verbal fluency 
Language 
Immediate and 
delayed recall 
NPSS: neuropsychiatric symptoms, VH: Visual Hallucination, ICDs: Impulse Control Disorders, DSM: Diagnostic and 
Statistical Manual of Mental Disorders, NPI: Neuropsychiatric Inventory, RCPM: 5HYDQ¶V Coloured Progressive Matrices, 
MMSE: Mini Mental State Examination, WRMF: Warrington Recognition Memory for Faces, BFRT: Benton Facial 
Recognition Test, BVFDT: Benton Visual Form Discrimination Test, WCST: Wisconsin Card Sorting Test, BJLOT: 
Benton Judgment Line Orientation Test, D-KEFS: Delis-Kaplan Executive Function System, ADAS-Cog: $O]KHLPHU¶V
Disease Assessment Scale-Cognition, TMT: Trail Making Test, FAB: Frontal Assessment Battery, CANTB: Cambridge 
Automated Neuropsychological Test Battery, COWAT: Controlled Oral Word Association Test, CVLT: California Verbal 
Learning Test. 
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Table 4: Summary of articles included in the review (Neuroanatomical of PD with 
neuropsychiatric symptoms)  
Authors NPSS Number of 
participants 
Imaging 
technique 
Affected brain area 
Ring et al. 
(1994) [99] 
Depression 10 PD with 
depression 
10 PD without 
depression 
PET Bilateral medial frontal cortex and 
anterior cingulate cortex 
Remy et al. 
(2005) [98] 
Depression 
 
20 PD 
 
PET Bilateral locus coeruleus and limbic 
system 
Matsui et al. 
(2007) [96] 
Depression 23 PD with 
depression 
27 PD without 
depression 
diffusion tensor 
MRI (ROI) 
Bilateral anterior cingulate 
bundle 
Feldmann et al. 
(2008) [92] 
Depression 23 PD with 
depression 
27 PD without 
depression 
VBM Left inferior orbito-frontal gyrus, 
bilateral rectal gyrus and right superior 
temporal pole 
Cardoso et al. 
(2009) [91] 
Depression 20 PD with 
depression 
18 PD without 
depression 
fMRI 
ROI 
Left mediodorsal nucleus of the 
thalamus and medial prefrontal cortex  
Kostic et al. 
(2010) [94] 
Depression 16 PD with 
depression 
24 PD without 
depression 
VBM Right posterior cingulate cortex, right 
inferior temporal gyrus and right 
hippocampus 
Li et al. (2010) 
[95] 
Depression 14 PD with 
depression 
18 PD without 
depression 
diffusion tensor 
MRI (ROI) 
Bilateral mediodorsal thalamus 
Petrovic et al. 
(2012) [97] 
Depression 34 PD with 
depression 
25 PD without 
depression 
MRI (White 
matter 
hyperintesities)   
No differences 
Huang et al. 
(2013) [93] 
Depression 26 PD PET (ROI) Bilateral amygdala 
Apathy   Bilateral anterior cingulate and 
orbitofrontal lobe 
Anxiety   Bilateral caudate nucleus 
Sheng et al. 
(2014) [100] 
Depression 20 PD with 
depression 
21 PD without 
depression 
Resting-state 
fMRI 
Left middle frontal gyrus and right 
inferior frontal gyrus, bilateral 
amygdala and lingual gyrus   
Isella et al. 
(2002) [45] 
Apathy 30 PD Morphometric 
MRI 
No correlation 
Le Jeune et al. 
(2009) [104] 
Apathy 12 PD PET Right middle/inferior frontal gyrus and 
bilateral posterior cingulate gyrus  
Reijnders et al. 
(2010) [50] 
Apathy 55 PD VBM Left precentral gyrus, bilateral inferior 
parietal gyrus, inferior frontal gyrus, 
insula and right posterior cingulate 
gyrus 
Skidmore et al. 
(2011) [101] 
Apathy 22 PD fMRI Right middle orbital-frontal gyrus, 
bilateral subgenual cingulate, left 
supplementary motor regions, left 
inferior parietal lobule and fusiform 
gyrus 
Depression   Right subgenual cingulate, bilateral 
cuneus, right geniculate and mesial 
frontal gyrus 
Robert et al. 
(2012) [67] 
Apathy 45 PD PET Right inferior/middle frontal gyrus, 
cuneus, insula and bilateral cerebellum 
Robert et al. 
(2014) [66] 
Apathy 36 PD PET Left posterior cingulate 
Nagano-Saito et 
al. (2004) [109] 
VH 11 PD with VH 
8 PD without VH 
PET Left superior frontal gyrus 
Oishi et al. 
(2005) [110] 
VH 24 PD with VH 
41 PD without VH 
SPECT Right superior/middle temporal gyri 
and fusiform gyrus 
35 
 
Ramirez-Ruiz 
et al. (2008) 
[77] 
VH 10 PD with VH 
10 PD without VH 
fMRI Right inferior/middle/superior frontal 
and anterior cingulate gyrus 
Ibarretxe-
Bilbao et al. 
(2008) [108] 
VH 44 PD VBM (ROI) Hippocampus (Anterior regions) 
Shin et al. 
(2012) [78] 
VH 46 PD with VH 
64 PD without VH 
VBM Right orbitofrontal, left temporal and 
thalamic areas  
Watanabe et al. 
(2013) [113] 
VH 13 PD with VH 
13 PD without VH 
VBM Bilateral dorsolateral prefrontal cortex, 
left rostral prefrontal cortex, left 
cingulate cortex, bilateral primary and 
secondary visual cortex and 
parahippocampal   
Pagonabarraga 
et al. (2013) 
[111] 
VH 17 PD with VH 
29 PD without VH 
VBM Bilateral inferior frontal cortex 
precuneus, cerebellum 
Gama et al. 
(2014) [107] 
VH 39 PD VBM Left opercula frontal gyrus 
Left superior frontal gyrus 
Steeves et al. 
(2009) [114] 
ICDs 7 PD with ICDs 
7 PD without ICDs 
 
PET Ventral striatum 
Biundo et al. 
(2011) [85] 
ICDs 33 PD with ICDs 
24 PD without ICDs 
VBM Bilateral middle/superior frontal gyrus 
NPSS: neuropsychiatric symptoms, VH: Visual Hallucination, ICDs: Impulse Control Disorders, MRI: Magnetic 
Resonance Imaging, VBM: Voxel-Based Morphometry, SPECT: Single Photon Emission Computed Tomography, PET: 
Positron Emission Tomography, fMRI: functional Magnetic Resonance Imaging, ROI: Region of Interest.  
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Figure 1 Flow chart of study selection process (Cognitive correlates of neuropsychiatric symptoms in PD) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Titles and abstracts 
identified and screened 
N= 1275 
Excluded N= 275 
Foreign language/not evaluating 
specific neuropsychiatric 
symptoms 
Full copies retrieved 
and assessed for 
eligibility N= 316 
Publications meeting 
inclusion criteria N= 41 
Depression N= 13 
Apathy N= 15 
Hallucinations N= 6 
ICDs N= 5 
Anxiety N=1 
Anxiety and apathy N= 1 
 
Excluded N= 217 
(Duplicate publications) 
Excluded N= 742 
Not focused on cognitive abilities  
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Figure 2 Flow chart of study selection process (Neural correlates of neuropsychiatric symptoms 
in PD) 
 
 
 
Excluded N= 217 
Not focused on neuroimaging in PD 
with neuropsychiatric symptoms 
Titles and abstracts 
identified and 
screened N= 338 
Excluded N= 43 
(Duplicate publications) 
Full copies retrieved 
and assessed for 
eligibility N= 78 
Excluded N= 52 
Foreign language/not 
evaluating specific 
neuropsychiatric symptoms 
Publications meeting inclusion 
criteria N= 26 
 
Depression N= 8 
Apathy N= 5 
Hallucinations N= 8 
ICDs N= 2 
Anxiety and depression N= 1 
Depression and apathy N= 2 
